Literature DB >> 15271792

KSHV viral cyclin binds to p27KIP1 in primary effusion lymphomas.

Annika Järviluoma1, Sonja Koopal, Susanna Räsänen, Tomi P Mäkelä, Päivi M Ojala.   

Abstract

Primary effusion lymphomas (PELs) represent a unique non-Hodgkin lymphoma that is consistently infected by Kaposi sarcoma herpesvirus (KSHV). PEL cells express high levels of the cell cycle inhibitor p27(KIP1) and yet proliferate actively. KSHV genome encodes a viral cyclin homolog, v-cyclin, which has previously been implicated in down-regulation of p27(KIP1) levels. To address how PEL cells can tolerate high p27(KIP1) levels, we investigated functional interactions between v-cyclin and p27(KIP1) using PEL-derived cell lines as a model system. Here we demonstrate that v-cyclin and p27(KIP1) stably associate in PEL cells in vivo suggesting an attractive model by which p27(KIP1) is inactivated in the actively proliferating PEL cells. Moreover, we show that v-cyclin and cyclin-dependent kinase 6 (CDK6) form an active kinase without p27(KIP1) and that CDK6 is the in vivo catalytic subunit of v-cyclin in PEL cells. These findings suggest that KSHV may promote oncogenesis in PEL by expressing v-cyclin, which both overrides negative cell cycle controls present in the PEL precursor cells and induces a strong proliferative signal via CDK6 kinase activity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15271792     DOI: 10.1182/blood-2004-05-1798

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

Review 1.  Molecular biology of KSHV in relation to AIDS-associated oncogenesis.

Authors:  Whitney Greene; Kurt Kuhne; Fengchun Ye; Jiguo Chen; Fuchun Zhou; Xiufen Lei; Shou-Jiang Gao
Journal:  Cancer Treat Res       Date:  2007

2.  Viral cyclin promotes KSHV-induced cellular transformation and tumorigenesis by overriding contact inhibition.

Authors:  Tiffany Jones; Suzane Ramos da Silva; Roble Bedolla; Fengchun Ye; Fuchun Zhou; Shou-Jiang Gao
Journal:  Cell Cycle       Date:  2014-01-13       Impact factor: 4.534

3.  Post-transplant lymphoproliferative disorders: role of viral infection, genetic lesions and antigen stimulation in the pathogenesis of the disease.

Authors:  Daniela Capello; Gianluca Gaidano
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-12-14       Impact factor: 2.576

4.  Nucleophosmin phosphorylation by v-cyclin-CDK6 controls KSHV latency.

Authors:  Grzegorz Sarek; Annika Järviluoma; Henna M Moore; Sari Tojkander; Salla Vartia; Peter Biberfeld; Marikki Laiho; Päivi M Ojala
Journal:  PLoS Pathog       Date:  2010-03-19       Impact factor: 6.823

5.  Phosphorylation of the cyclin-dependent kinase inhibitor p21Cip1 on serine 130 is essential for viral cyclin-mediated bypass of a p21Cip1-imposed G1 arrest.

Authors:  Annika Järviluoma; Emma S Child; Grzegorz Sarek; Papinya Sirimongkolkasem; Gordon Peters; Päivi M Ojala; David J Mann
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

6.  The Ubiquitin System and Kaposi's Sarcoma-Associated Herpesvirus.

Authors:  Akira Ashizawa; Chizuka Higashi; Kazuki Masuda; Rie Ohga; Takahiro Taira; Masahiro Fujimuro
Journal:  Front Microbiol       Date:  2012-02-23       Impact factor: 5.640

Review 7.  Modulation of DNA damage and repair pathways by human tumour viruses.

Authors:  Robert Hollingworth; Roger J Grand
Journal:  Viruses       Date:  2015-05-22       Impact factor: 5.048

8.  Preparation and application of polyclonal antibodiesagainst KSHV v-cyclin.

Authors:  Min Xue; Yuanyuan Guo; Qin Yan; Di Qin; Chun Lu
Journal:  J Biomed Res       Date:  2013-04-20

9.  Viral oncogene-induced DNA damage response is activated in Kaposi sarcoma tumorigenesis.

Authors:  Sonja Koopal; Johanna H Furuhjelm; Annika Järviluoma; Sari Jäämaa; Pawan Pyakurel; Christel Pussinen; Maria Wirzenius; Peter Biberfeld; Kari Alitalo; Marikki Laiho; Päivi M Ojala
Journal:  PLoS Pathog       Date:  2007-09-07       Impact factor: 6.823

10.  Activation of DNA Damage Response Pathways during Lytic Replication of KSHV.

Authors:  Robert Hollingworth; George L Skalka; Grant S Stewart; Andrew D Hislop; David J Blackbourn; Roger J Grand
Journal:  Viruses       Date:  2015-06-05       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.